Research article Special Issues

Mathematical modeling of tumor growth: the MCF-7 breast cancer cell line

  • Breast cancer is the second most commonly diagnosed cancer in women worldwide. MCF-7 cell line is an extensively studied human breast cancer cell line. This cell line expresses estrogen receptors, and the growth of MCF-7 cells is hormone dependent. In this study, a mathematical model, which governs MCF-7 cell growth with interaction among tumor cells, estradiol, natural killer (NK) cells, cytotoxic T lymphocytes (CTLs) or CD8+ T cells, and white blood cells (WBCs), is proposed. Experimental data are used to determine functional forms and parameter values. Breast tumor growth is then studied using the mathematical model. The results obtained from numerical simulation are compared with those from clinical and experimental studies. The system has three coexisting stable equilibria representing the tumor free state, a microscopic tumor, and a large tumor. Numerical simulation shows that an immune system is able to eliminate or control a tumor with a restricted initial size. A healthy immune system is able to effectively eliminate a small tumor or produces long-term dormancy. An immune system with WBC count at the low parts of the normal ranges or with temporary low NK cell count is able to eliminate a smaller tumor. The cytotoxicity of CTLs plays an important role in immune surveillance. The association between the circulating estradiol level and cancer risk is not significant.

    Citation: Hsiu-Chuan Wei. Mathematical modeling of tumor growth: the MCF-7 breast cancer cell line[J]. Mathematical Biosciences and Engineering, 2019, 16(6): 6512-6535. doi: 10.3934/mbe.2019325

    Related Papers:

    [1] Marcin Choiński, Mariusz Bodzioch, Urszula Foryś . A non-standard discretized SIS model of epidemics. Mathematical Biosciences and Engineering, 2022, 19(1): 115-133. doi: 10.3934/mbe.2022006
    [2] Andreas Widder, Christian Kuehn . Heterogeneous population dynamics and scaling laws near epidemic outbreaks. Mathematical Biosciences and Engineering, 2016, 13(5): 1093-1118. doi: 10.3934/mbe.2016032
    [3] Marcin Choiński . A contiunous-time SIS criss-cross model of co-infection in a heterogeneous population. Mathematical Biosciences and Engineering, 2025, 22(5): 1055-1080. doi: 10.3934/mbe.2025038
    [4] Yicang Zhou, Zhien Ma . Global stability of a class of discrete age-structured SIS models with immigration. Mathematical Biosciences and Engineering, 2009, 6(2): 409-425. doi: 10.3934/mbe.2009.6.409
    [5] Jianquan Li, Zhien Ma, Fred Brauer . Global analysis of discrete-time SI and SIS epidemic models. Mathematical Biosciences and Engineering, 2007, 4(4): 699-710. doi: 10.3934/mbe.2007.4.699
    [6] Qianhong Zhang, Fubiao Lin, Xiaoying Zhong . On discrete time Beverton-Holt population model with fuzzy environment. Mathematical Biosciences and Engineering, 2019, 16(3): 1471-1488. doi: 10.3934/mbe.2019071
    [7] Ke Guo, Wanbiao Ma . Global dynamics of an SI epidemic model with nonlinear incidence rate, feedback controls and time delays. Mathematical Biosciences and Engineering, 2021, 18(1): 643-672. doi: 10.3934/mbe.2021035
    [8] Ning Yu, Xue Zhang . Discrete stage-structured tick population dynamical system with diapause and control. Mathematical Biosciences and Engineering, 2022, 19(12): 12981-13006. doi: 10.3934/mbe.2022606
    [9] Nazanin Zaker, Christina A. Cobbold, Frithjof Lutscher . The effect of landscape fragmentation on Turing-pattern formation. Mathematical Biosciences and Engineering, 2022, 19(3): 2506-2537. doi: 10.3934/mbe.2022116
    [10] Hui Cao, Yicang Zhou, Zhien Ma . Bifurcation analysis of a discrete SIS model with bilinear incidence depending on new infection. Mathematical Biosciences and Engineering, 2013, 10(5&6): 1399-1417. doi: 10.3934/mbe.2013.10.1399
  • Breast cancer is the second most commonly diagnosed cancer in women worldwide. MCF-7 cell line is an extensively studied human breast cancer cell line. This cell line expresses estrogen receptors, and the growth of MCF-7 cells is hormone dependent. In this study, a mathematical model, which governs MCF-7 cell growth with interaction among tumor cells, estradiol, natural killer (NK) cells, cytotoxic T lymphocytes (CTLs) or CD8+ T cells, and white blood cells (WBCs), is proposed. Experimental data are used to determine functional forms and parameter values. Breast tumor growth is then studied using the mathematical model. The results obtained from numerical simulation are compared with those from clinical and experimental studies. The system has three coexisting stable equilibria representing the tumor free state, a microscopic tumor, and a large tumor. Numerical simulation shows that an immune system is able to eliminate or control a tumor with a restricted initial size. A healthy immune system is able to effectively eliminate a small tumor or produces long-term dormancy. An immune system with WBC count at the low parts of the normal ranges or with temporary low NK cell count is able to eliminate a smaller tumor. The cytotoxicity of CTLs plays an important role in immune surveillance. The association between the circulating estradiol level and cancer risk is not significant.


    The most important tumor suppressor p53 has a key role in regulating a number of cellular responses upon various stresses including DNA damage and oncogene activation [1,2]. Depending on the type and severity of the damage, p53-mediated responses include cell cycle arrest, cellular senescence and apoptosis, which can be triggered through regulating the expression of different downstream genes [3,4]. These responses are closely related to p53 dynamics, where p53 keeps low level in unstressed cells, whereas a high level of p53 induces apoptosis to destroy irreparably damaged cells [5,6]. More interestingly, the oscillation dynamics of p53 may initiate cell cycle arrest or apoptosis depending on the number of p53 pulses [7,8]. Therefore, it is meaningful to explore p53 dynamics for understanding cellular response in response to different conditions. Furthermore, p53 dynamics can be investigated through simulating the mathematical models of p53 gene regulatory network with p53, it upstream regulators, downstream target genes and feedback loops [9,10].

    A number of mathematical models depicting p53 gene regulatory network have been established to explore p53 dynamics in response to different conditions from theoretical analyses and numerical simulations [7,8,11]. Typically, an integrated model of p53 gene regulatory network with four modules was proposed by Zhang et al., who demonstrated that the number of p53 pulses determined cell fates upon DNA damage [7,8]. Based on the integrated model and experiment results, a mathematical model of p53 gene regulatory network regulated by Programmed Cell Death 5(PDCD5) has been developed so as to reveal that PDCD5 modulates cell fate decisions as a co-activator of p53 [12,13]. Furthermore, the effects of rate constants in the p53 gene regulatory network on p53 dynamics are explored through bifurcation analyses and potential landscapes [14,15]. However, the transcriptional and translational processes in the model are seen as instant. Actually, slow and complex transcriptional and translational processes as the basic steps of gene expression in cells are usually related to long time delay [16]. Time delays in various networks, such as neural networks and disc dynamos with viscous friction, have important impact on the dynamics in the network, which are explored through stability and bifurcation analyses [17,18,19,20]. Also, more researches explore the effect of time delays in some p53 gene regulatory networks on p53 oscillation [21]. However, the effect of time delay on p53 oscillation in p53 gene regulatory network regulated by PDCD5 has not been considered.

    Inspired by these considerations, we introduce a time delay of the transcriptional and translational processes of Mdm2 activated by p53 into p53 gene regulatory network regulated by PDCD5 in ref. [22]. The local stability of positive equilibrium of the model are demonstrated through analyzing the characteristic equations of the corresponding linearized system for two cases without and with time delay. Also, these stability are verified through time series, the distribution of characteristic roots, one-parameter bifurcation diagram and potential landscapes. Then, two-parameter bifurcation diagrams of time delay with the concentration of PDCD5 and four typical rate parameters, vp53, dp53, vMdm2 and dMdm2 are carried out to explore their effect on the oscillation dynamic of p53.

    This paper is organized as follows. The p53 gene regulatory network regulated by PDCD5 is given in Section 2. In Section 3, we analyze the local stability of positive equilibrium of the model by means of stability theory for two cases without and with time delay. Then numerical simulations and bifurcation analyses are given in Section 4. Finally, we conclude the paper in Section 5.

    The model of p53 gene regulatory network regulated by PDCD5 is illustrated in Figure 1, which was established in Ref. [22]. Double strand breaks (DSBs) induced by various stresses activate ATM monomers, which further phosphorylate p53 at Ser-15 in the nucleus(p53) and Mdm2 at Ser-395 in the cytoplasm (Mdm2395Pcyt). Phosphorylated p53 in the nucleus inhibits ATM activity through activating it inhibitor Wip1 [23,24,25]. Additionally, Mdm2 protein in the cytoplasm(Mdm2cyt) transforms with Mdm2395Pcyt and Mdm2 protein in the nucleus (Mdm2nuc). Furthermore, Mdm2395Pcyt stimulates p53 translation through interacting with p53 mRNA while Mdm2nuc promotes p53 degradation by binding p53 and increasing it ubiquitination [26]. Besides, PDCD5 functions as a positive regulator of p53 through accelerating the degradation of Mdm2nuc and inhibiting the degradation of p53 by Mdm2nuc [22]. Here, phosphorylated p53 accelerates the production of Mdm2cyt through promoting the expression of Mdm2 gene. As we know, it takes some time from gene transcription to protein production, so we introduce a time delay into the interaction of p53 with Mdm2cyt. The model equations of the p53 gene regulatory network with time delay are given as follows.

    {dx(t)dt=vp53f1(m(t))f2(z(t))dp53f3(w(t))x(t),dy(t)dt=vMdm2f4(x(tτ))dMdm2y(t)kiny(t)+koutw(t)kpf5(m(t))y(t)+kqz(t),dz(t)dt=kpf5(m(t))y(t)kqz(t)g0dMdm2z(t),dw(t)dt=kiny(t)koutw(t)(1+r2p)dMdm2w(t),dm(t)dt=vAdATMf6(x(t))m(t), (2.1)
    Figure 1.  (Color online) Illustration of the PDCD5-mediated p53-Mdm2 pathway. State transitions are represented by arrow-headed solid lines, degradation is represented by dashed-lines, and the promotion and inhibition are separately denoted by solid-circle headed and bar-headed lines, respectively.

    where

    f1(m(t))=(1ρ0)+ρ0m4(t)K40+m4(t),f2(z(t))=(1ρ1)+ρ1z4(t)K41+z4(t),f3(w(t))=(1ρ2)+ρ2w4(t)K42(p)+w4(t),K2(p)=¯k0((1r1)+r1(αp)41+(αp)4),f4(x(t))=(1ρ3)+ρ3x4(t)K43+x4(t),f5(m(t))=(1ρ4)+ρ4m2(t)K24+m2(t),f6(x(t))=(1ρ5)+ρ5x4(t)K45+x4(t).

    Here x(t), y(t), z(t), w(t) and m(t) represent the concentration at time t of active p53, Mdm2cyt, Mdm2395Pcyt, Mdm2nuc and ATM proteins. The biological significance and values of all parameters in the model are given in Table 1.

    Table 1.  Typical parameter values. Cs= simulated concentration units [22].
    Parameters Description Value
    vp53 Maximum p53 production rate 0.8 Csmin1
    ρ0 Regulation strength of p53 activation by ATM 0.9
    K0 EC50 of p53 activation by ATM 0.3 Cs
    ρ1 Regulation strength of p53 translation by Mdm2395Pcyt 0.98
    K1 EC50 of p53 translation by Mdm2395Pcyt 0.057 Cs
    dp53 Maximum degradation rate of p53 0.53 min1
    ρ2 Regulation strength of p53 degradation by Mdm2nuc 0.97
    ¯k0 Maximum EC50 of p53 degradation by Mdm2nuc 0.09 Cs
    r1 Strength of EC50 K2 by PDCD5 0.8
    α Regulation efficiency of PDCD5 to the EC50 K2 3.3 C1s
    vMdm2 Maximum production rate of Mdm2cyt 0.135 min1
    ρ3 Regulation strength of Mdm2 production by p53 0.98
    K3 EC50 of Mdm2 production by p53 4.43 Cs
    kin Shuttle rate of Mdm2 into nucleus 0.14 min1
    kout Shuttle rate of Mdm2 out of nucleus 0.01 min1
    kp Maximum phosphorylation rate of Mdm2 at Ser395 0.65 min1
    ρ4 Regulation strength of Mdm2 phosphorylation by ATM 0.9
    K4 EC40 of Mdm2 phosphorylation by ATM 1 Cs
    kq ATM dephosphorylation rate 0.24 min1
    dMdm2 Mdm2 degradation rate 0.034 min1
    g0 Increase factor of Mdm2 degradation rate by phosphorylation 3.58
    r2 PDCD5 dependent Mdm2 degradation rate coefficient 1.5 C1S
    p PDCD5 level during DNA damage 1.6 Cs
    dATM Active ATM degradation rate 0.53
    ρ5 Regulation strength of active ATM degradation by p53 0.9
    K5 EC50 of active ATM degradation by p53 1 Cs
    vA Active ATM production rate during DNA damage 1.2 min1

     | Show Table
    DownLoad: CSV

    In this section, the local stability of positive equilibrium E=(X,Y,Z,W,M) are analyzed through stability theory for without and with time delay. Let ¯x(t)=x(t)X, ¯y(t)=y(t)Y, ¯z(t)=z(t)Z, ¯w(t)=w(t)W, ¯m(t)=m(t)M, the linearization of system (2.1) at E is given as follows,

    {d¯x(t)dt=B1¯x(t)+B2¯z(t)+B3¯w(t)+B4¯m(t),d¯y(t)dt=B16¯x(tτ)+B5¯y(t)+B6¯z(t)+B7¯w(t)+B8¯m(t),d¯z(t)dt=B9¯y(t)+B10¯z(t)+B11¯m(t),d¯w(t)dt=B12¯y(t)+B13¯w(t),d¯x(t)dt=B14¯x(t)+B15¯m(t), (3.1)

    where

    B1=dp53f3(W),B2=vp53f1(M)f2(Z),B3=dp53f3(W)X,B4=vp53f1(M)f2(Z),B5=(dMdm2+kin+kpf5(M)),B6=kq,B7=kout,B8=kpf5(M)Y,B9=kpf5(M),B10=(kq+g0dMdm2),B11=kpf5(M)Y,B12=kin,B13=(kout+(1+r2p)dMdm2),B14=dATMf6(X)M,B15=dATMf6(X),B16=vMdm2f4(X).

    The system (3.1) can be written as the form of matrix:

    (˙¯x(t)˙¯y(t)˙¯z(t)˙¯w(t)˙¯m(t))=D1(¯x(t)¯y(t)¯z(t)¯w(t)¯m(t))+D2(¯x(tτ)¯y(tτ)¯z(tτ)¯w(tτ)¯m(tτ)), (3.2)

    where

    D1=(B10B2B3B40B5B6B7B80B9B100B110B120B130B14000B15),D2=(00000B160000000000000000000).

    Using Laplace transform,

    L[f(tT)]=esTF(s),L[f(t)]=F(s),L[f(t)]=sF(s)F(0),

    Eq (3.2) can be given as follows:

    λ(ˆx(t)ˆy(t)ˆz(t)ˆw(t)ˆm(t))(ˆx(0)ˆy(0)ˆz(0)ˆw(0)ˆm(0))=D1(ˆx(t)ˆy(t)ˆz(t)ˆw(t)ˆm(t))+D2eλτ(ˆx(t)ˆy(t)ˆz(t)ˆw(t)ˆm(t)). (3.3)

    Without loss of generality, let

    (ˆx(0)ˆy(0)ˆm(0)ˆw(0)ˆs(0))=0.

    Then, the characteristic equation of the linear system (3.1) is give as follows:

    det(λID2eλτD1)=0. (3.4)

    That is:

    λ5+a1λ4+a2λ3+a3λ2+a4λ+a5+(A2λ2+A1λ+A0)eλτ=0, (3.5)

    where

    a1=(B1+B5+B10+B13+B15),a2=B4B14B7B12B6B9+B13B15+B10B15+B10B13+B1B15+B1B10+B5B15+B5B13+B5B10+B1B5+B1B13,a3=B2B11B14+B4B5B14+B4B10B14+B4B13B14+B7B12B15B1B10B15B1B13B15B1B10B13B5B13B15B5B10B15B5B10B13+B1B7B12+B1B6B9B1B5B15+B6B9B13+B6B9B15B10B13B15B1B5B13B1B5B10+B7B10B12,a4=B12B3B8B14+B12B4B7B14+B2B5B11B14+B2B11B13B14B4B5B10B14+B1B5B10B13B4B10B13B14B7B10B12B15B1B7B10B12B1B6B9B13B1B6B9B15B2B8B9B14B6B9B13B15+B5B10B13B15+B1B5B13B15+B1B5B10B15B4B5B13B14B1B7B12B15+B1B10B13B15+B4B6B9B14,a5=B3B6B11B12B14B2B5B11B13B14+B2B8B9B13B14+B4B5B10B13B14+B1B7B10B12B15+B1B6B9B13B15+B12B3B8B10B14B12B4B7B10B14+B2B7B11B12B14B4B6B9B13B14B1B5B10B13B15,A0=B3B10B12B15B16B2B9B13B15B16,A1=B3B12B15B16+B3B10B12B16+B2B9B13B16+B2B9B15B16,A2=B3B12B16B2B9B16.

    For τ=0, Eq (3.5) becomes

    λ5+a1λ4+a2λ3+(a3+A2)λ2+(a4+A1)λ+a5+A0=0. (3.6)

    The conditions for local stability of E=(X,Y,Z,W,M) are give in Theorem 3.1 according to the Routh-Hurwitz criterion [27].

    Theorem 3.1. E=(X,Y,Z,W,M) is locally asymptotically stable when all roots of Eq (3.6) have negative real parts, the following conditions (H) should be satisfied.

    (H):

    Δ1=a1>0,Δ2=a1a2a3A2>0,Δ3=(a3+A2)(a1a2a3A2)a1(a1(a4+A1)a5A0)>0,Δ4=(a5+A0)(a2a3+a2A2a5A0a1(a22a4A1))+(a4+A1)(a1(a2a3+a2A2)a21(a4+A1)(a3+A2)2+a1(a5+A0))>0,Δ5=a5+A0>0.

    For τ0, let iω(ω>0) be a root of Eq (3.5), so ω satisfies the following equation:

    iω5+a1ω4ia2ω3a3ω2+ia4ω+a5+(A0A2ω2+iA1ω)(cos(ωτ)isin(ωτ))=0.

    Separating the real and imaginary parts, we have

    {a1ω4a3ω2+a5=(A0A2ω2)cos(ωτ)A1ωsin(ωτ),ω5a2ω3+a4ω=A1ωcos(ωτ)+(A0A2ω2)sin(ωτ). (3.7)

    Squaring both sides of each equation and then adding them up leads to

    ω10+(a212a2)ω8+(a22+2a42a1a3)ω6+(a232a2a4+2a1a5A22)ω4+(a242a3a5A21+2A0A2)ω2+a25A20=0. (3.8)

    Let z=w2, p=a212a2, q=a22+2a42a1a3, r=a232a2a4+2a1a5A22, u=a242a3a5A21+2A0A2 and v=a25A20. Then Eq (3.8) can be written as

    z5+pz4+qz3+rz2+uz+v=0. (3.9)

    Some lemmas for establishing the distribution of positive real roots of Eq (3.9) are given as follows [28].

    Lemma 3.2. If v<0, then Eq (3.9) has at least one positive root.

    Proof. Denote h(z)=z5+pz4+qz3+rz2+uz+v. Since h(0)=v<0 and limz+h(z)=+. Hence, there exists a z0>0 such that h(z0)=0. The proof is complete.

    For v0, considering the following equation:

    h(z)=5z4+4pz3+3qz2+2rz+u=0. (3.10)

    Let z=yp5, then Eq (3.10) is changed into:

    y4+p1y2+q1y+r1=0, (3.11)

    where

    p1=625p2+35q,q1=8125p3+625pq+25r,r1=3625p4+3125p2q225pr+15u.

    If q1=0, then the four roots of Eq (3.11) are as follows:

    y1=p1+Δ02,y2=p1+Δ02,y3=p1Δ02,y4=p1Δ02,

    where Δ0=p214r1. Thus zi=yip5, i=1,2,3,4 are the roots of Eq (3.10). Then we have the following lemma.

    Lemma 3.3. Suppose that v0 and q1=0.

    (i) If Δ0<0, then Eq (3.9) has no positive real roots.

    (ii) If Δ00, p10 and r1>0, then Eq (3.9) has no positive real roots.

    (iii) If (i) and (ii) are not satisfied, then Eq (3.9) has positive real roots if and only if there exists at least one z{z1,z2,z3,z4} such that z>0 and h(z)0.

    Proof. (ⅰ) If Δ0<0, then Eq (3.10) has no real roots. Since limz+h(z)=+, so h(z)>0 for zR. Hence, h(0)=v0 leads to h(z)0 when z(0,+).

    (ⅱ) If Δ00, p10 and r1>0, then h(z) has no zero in (,+). It is similar to (ⅰ) that h(z)0 for any z(0,+).

    (ⅲ) The sufficiency holds obviously. We will prove the necessity. If Δ00, then Eq (3.11) has only four roots y1,y2,y3,y4, so Eq (3.10) has only four roots z1,z2,z3,z4 at least z1 is a real root. We assume that z1,z2,z3,z4 are all real. This means that h(z) has at most four stationary points at z1,z2,z3,z4. If it is not true, we will have that either z10 or z1>0 and min{h(zi):zi0,i=1,2,3,4}>0. If z10, then h(z)0 in (0,+). Since h(0)=v0 is the strict minimum of h(z) for z0 which means h(z)>0 when z(0,+). If z1>0 and min{h(zi):zi0,i=1,2,3,4}>0, since h(z) is the derivable function and limz+h(z)=+, then we have minz>0h(z)=min{h(zi):zi0,i=1,2,3,4}>0. The proof of the necessity is done. We finish the proof.

    If q10. Thinking about the solution of Eq (3.11):

    q214(sp1)(s24r1)=0, (3.12)

    that is

    s3p1s24r1s+4p1r1q21=0.

    Let

    p2=13p214r1,q2=227p31+83p1r1q21,Δ1=127p32+14q22,σ=12+32i.

    So, Eq (3.12) has the following three roots

    s1=3q22+Δ1+3q22Δ1+p13,s2=σ3q22+Δ1+σ23q22Δ1+p13,s3=σ23q22+Δ1+σ3q22Δ1+p13.

    Let s=s1p1 (since p1 is not a root of Eq (3.12)). Equation (3.11) is equivalent to

    y4+sy2+(s)24[(sp1)y2q1y+(s)24r1]=0. (3.13)

    For Eq (3.13), Eq (3.12) indicates that the formula in square brackets is a perfect square.

    If s>p1, then Eq (3.13) is

    (y2+s2)2(sp1yq12sp1)2=0.

    After factorization, we get

    y2+sp1yq12sp1+s2=0

    and

    y2sp1y+q12sp1+s2=0.

    Let

    Δ2=sp1+2q1sp1,Δ3=sp12q1sp1.

    Then we obtain the four roots of Eq (3.11)

    y1=sp1+Δ22,y2=sp1Δ22,y3=sp1+Δ32,y4=sp1Δ32.

    So zi=yip5, i=1,2,3,4 are the roots of Eq (3.10). Thus we can get the following lemma.

    Lemma 3.4. Suppose that v0, q10 and s>p1.

    (i) If Δ2<0 and Δ3<0, then Eq (3.9) has no positive real roots.

    (ii) If (i) is not satisfied, then Eq (3.9) has positive real roots if and only if there exists at least one z{z1,z2,z3,z4} such that z>0 and h(z)0.

    Proof. We omit the proof since it is similar to Lemma 3.3.

    Finally, if s<p1, then Eq (3.13) is

    (y2+s2)2+(p1syq12p1s)2=0. (3.14)

    Let ¯z=q12(p1s)p5, we have the following lemma.

    Lemma 3.5. Suppose that v0, q10 and s<p1, then Eq (3.9) has positive real roots if and only if q214(p1s)2+s2=0, ¯z>0 and h(¯z)0.

    Proof. If Eq (3.13) has a real root y0, which satisfies

    y0=q12(p1s),y20=s2,

    so

    q214(p1s)2+s2=0.

    Therefore, Eq (3.13) has a real root y0 if and only if q214(p1s)2+s2=0. The rest of the proof is similar to Lemma 3.3, we omit it.

    Lemmas 3.2, 3.3, 3.4 and 3.5 give the sufficient and necessary conditions of existence of positive roots of Eq (3.9).

    Suppose that Eq (3.9) has five positive roots zk,i=1,2,3,4,5. Then Eq (3.8) has five positive roots ωk=zk, i=1,2,3,4,5. From Eq (3.8), we obtain the corresponding τ(k)j>0 and the characteristic equation (3.5) has purely imaginary roots.

    τ(k)j=1ωk[arccos((A2a1A1)ω6(A0A2ω2)2+A21ω2+(A1a2A0a1A2a3)ω4(A0A2ω2)2+A21ω2+(A0a3+A2a5A1a4)ω2A0a5(A0A2ω2)2+A21ω2)+2jπ],k=1,2,3,4,5,j=0,1,2,.

    It is obvious that limjτ(k)j= for k=1,2,3,4,5. Next we can define

    τ0=τk0j0=min1k5,j1τ(k)j,ω0=ωk0,z0=zk0. (3.15)

    On the basis of the above analysis, we obtain the conditions that all roots of Eq (3.5) have negative real parts in the following lemma.

    Lemma 3.6. (i) If one of the followings holds:(a) v<0; (b) v0, q1=0, Δ00 and p1<0 or r10 and there exist z{z1,z2,z3,z4} such that z>0 and h(z)0; (c) v0, q10, s>p1, Δ20 or Δ30 and there exist z{z1,z2,z3,z4} such that z>0 and h(z)0; (d) v0, q10, s<p1, q214(p1s)2+s2=0, ¯z>0 and h(¯z)0, then all roots of the characteristic equation (3.5) have negative real parts when τ(0,τ0).

    (ii) If the conditions (a)-(d) of (i) are all not satisfied, then all roots of Eq (3.5) have negative real parts for all τ>0.

    Proof. Lemmas 3.2, 3.3, 3.4 and 3.5 shows that Eq (3.5) has no roots with zero real part for all τ>0 if the conditions (a)–(d) of (ⅰ) are not satisfied. If one of (a)–(d) holds, when ττ(k)j, Eq (3.5) has no roots with zero real part and τ0 is the minimum value of τ, which make equation (3.5) has purely imaginary roots. We get the conclusion of the lemma.

    Next, we want to prove the system (2.1) can undergo Hopf bifurcation at τ=τ0.

    Let

    λ(τ)=α(τ)+iω(τ) (3.16)

    be the root of Eq (3.5) satisfying α(τ0)=0, ω(τ0)=ω0. We have the next lemma.

    Lemma 3.7. Suppose h(z0)0. If τ=τ0, then ±iω0 is a pair of simple purely imaginary roots of Eq (3.5).

    Proof. If iω0 is not simple, then ω0 must satisfy

    ddλ[λ5+a1λ4+a2λ3+a3λ2+a4λ+a5+(A2λ2+A1λ+A0)eλτ]|λ=iω0=0.

    This implies that

    {5ω403a2ω20+a4=(τA0A2ω20τA1)cos(ω0τ0)+(A1ω0τ2A2ω0)sin(ω0τ0),4a1ω30+2a3ω0=(A1ω0τ2A2ω0)cos(ω0τ0)(τA0A2ω20τA1)sin(ω0τ0). (3.17)

    Meanwhile, from Eq (3.7) we konw that ω0 satisfies

    {a1ω40a3ω20+a5=(A0A2ω20)cos(ω0τ)A1ω0sin(ω0τ),ω50a2ω30+a4ω0=A1ω0cos(ω0τ)+(A0A2ω20)sin(ω0τ). (3.18)

    Thus, we have

    (A22ω40+A21ω202A0A2ω20+A20)[5ω80+4(a212a2)ω60+3(a22+2a42a1a3)ω40+2(a232a2a4+2a1a5A22)ω20+(a242a3a5A21+2A0A2)]+(2A0A22A22ω20A21)[ω100+(a212a2)ω80+(a22+2a42a1a3)ω60+(a232a2a4+2a1a5A22)ω40+(a242a3a5A21+2A0A2)ω20+(a25A20)]=0. (3.19)

    According to Eq (3.9) and ω20=z0, Eq (3.19) becomes

    (A22z2+A21z2A0A2z+A20)(5z4+4pz3+3qz2+2rz+u)+(2A0A22A22zA21)(z5+pz4+qz3+rz2+uz+v)=0. (3.20)

    Notice that h(z)=z5+pz4+qz3+rz2+uz+v and h(z)=5z4+4pz3+3qz2+2rz+u, Eq (3.20) becomes ((A0A2z0)2+A21z0)h(z0)=0. we obtain a contradiction to the condition h(z0)0. This proves the conclusion.

    Next, we will get the conditions for dRe(λ(τ0))dτ>0 in Lemma 3.8.

    Lemma 3.8. If the conditions of Lemma 3.6 (i) are satisfied, then dRe(λ(τ0))dτ>0.

    Proof. Differentiating both sides of Eq (3.5) with respect to τ gives

    (d(λ(τ))dτ)1=5λ4+4a1λ3+3a2λ2+2a3λ+a4+eλτ(2A2λ+A1)eλτ(A2λ3+A1λ2+A0λ)τλ. (3.21)

    Therefore

    [d(Re(λ(τ)))dτ]1|τ=τ0=5ω80+4pω60+3qω40+2rω20+u(A0A2ω20)2+A21ω20=h(z0)(A0A2ω20)2+A21ω200. (3.22)

    If dReλ(τ0)dτ<0, then equation (3.5) has a root with positive real part for τ<τ0 and close to τ0, which contradicts Lemma 3.6 (ⅰ). This completes the proof.

    To sum up, we get the following theorems.

    Theorem 3.9. Let ω0, z0, τ0, and λ(τ) be defined by Eq (3.15) and (3.16), respectively.

    (i) If the conditions (a)–(d) of Lemma 3.6 are not satisfied, then all the roots of Eq (3.5) have negative real parts for all τ>0.

    (ii) If one of the conditions (a)–(d) of Lemma 3.6 is satisfied, then all the roots of Eq (3.5) have negative real parts when τ(0,τ0); when τ=τ0 and h(z0)0, then ±iω0 is a pair of simple purely imaginary roots of Eq (3.5) and all other roots have negative real parts. In addition, dReλ(τ0)dτ>0 and Eq (3.5) has at least one root with positive real part when τ(τ0,τ1), when τ1 is the first value of τ>τ0 such that Eq (3.5) has purely imaginary root.

    Theorem 3.10. Let ω0, z0, τ0, and λ(τ) be defined by Eq (3.15) and (3.16), respectively.

    (i) If the conditions (a)–(d) of Lemma 3.6 are not satisfied, then the positive equilibrium point E=(X,Y,Z,W,M) of system (2.1) is asymptotically stable for all τ>0;

    (ii) If one of the conditions (a)–(d) of Lemma 3.6 is satisfied, then the positive equilibrium point E=(X,Y,Z,W,M) of system (2.1) is asymptotically stable when τ(0,τ0);

    (iii) If conditions (a)–(d) of Lemma 3.6 is satisfied, and h(z0)0, system (2.1) undergoes a Hopf bifurcation at E=(X,Y,Z,W,M) when τ=τ0.

    In summary, Theorems 3.1 and 3.10 give the local stability of positive equilibrium E=(X,Y,Z,W,M) of system (2.1) and the conditions undergoing Hopf bifurcation without and with time delay, respectively. In the following, some numerical simulations are given to verify the correctness of these theorems.

    In this section, Theorems 3.1 and 3.10 are verified through time series of the concentrations of active p53(x), total Mdm2(y+z+w), ATM(m) and the eigenvalues of Eq (3.5) for τ=0 and τ0. Besides, one-parameter bifurcation diagram of the concentrations of active p53(x) with respect to τ and potential landscapes of active p53(x) and total Mdm2(y+z+w) are given to verify the correctness of Theorem 3.10. These figures are realized by MATLAB software.

    In case Ⅰ of τ=0, a positive equilibrium E=(3.0492,0.0770,0.1184,0.0858,2.2877) of system (2.1) is obtained for parameters in Table 1. Substituting these parameters into Δi(i=1,2,3,4,5), we have Δ1=1.9910>0, Δ2=2.2370>0, Δ3=0.6136>0, Δ4=0.0197>0 and Δ5=0.0134>0. The condition (H) in Theorem 3.1 is satisfied, so the positive equilibrium E is asymptotically stable, which is verified through numerical simulations in Figure 2. Figure 2(a) shows that the concentrations of x, y+z+w and m firstly increase and then converge to the positive equilibrium E. Also, all roots of the characteristic equation (3.6) at the positive equilibrium point E have negative real parts, as shown in Figure 2(b).

    Figure 2.  (Color online) (a) Time series of the concentrations of active p53(x), total Mdm2 (y+z+w) and ATM(m) without time delay(τ=0). (b) Roots of characteristic equation (3.6) at E=(X,Y,Z,W,M). (λ) and (λ) are real and imaginary parts of these roots.

    For case Ⅱ τ0, substituting the same positive equilibrium E with τ=0 and the parameters in Table 1 into Eq (3.8), we get

    ω10+1.2866ω8+0.3695ω6+0.0246ω44.4345×104ω21.2282×104=0. (4.1)

    Equation (4.1) has a positive root ω0=0.2342, then z0=ω20=0.0548 and τ0=2.1217 from Eq (3.8). Note that v=1.2282×104<0 and h(z0)=0.00650, the conditions (ⅱ) and (ⅲ) in Theorem 3.10 are satisfied, so the positive equilibrium E is asymptotically stable when τ(0,τ0) and system (2.1) undergoes Hopf bifurcation at τ0=2.1217, where E loses stability and a stable limit cycle appears. The correctness of Theorem 3.10 is verified by the following numerical simulations in Figures 36. Figure 3(a) describes one-parameter bifurcation diagram of x with respect to τ, where black solid and dashed lines are stable and unstable equilibria, and green solid dots are the maxima and minima of the stable limit cycle. As is shown in Figure 3(a), system (2.1) converges to the positive equilibrium E for τ<τ0 and undergoes Hopf bifurcation at HB point with τ=τ0, then the positive equilibrium E loses stability and a stable limit cycle appears for τ>τ0. Also, the stability of the positive equilibrium E is further verified through the maximum real part of the eigenvalues of the characteristic equation (3.5) in Figure 3(b), where maximum real part is negative for τ<τ0 and zero at τ=τ0 then positive for τ>τ0.

    Figure 3.  (Color online) (a) One-parameter bifurcation diagram of the concentration of active p53(x) with respect to τ. Black solid and dashed lines are stable and unstable equilibria, and green solid dots are the maxima and minima of the stable limit cycle. (b) The maximum real part of the eigenvalues of the characteristic equation (3.5) with respect to τ. HB is Hopf bifurcation point.
    Figure 4.  (Color online) Time series of the concentrations of active p53(x), total Mdm2 (y+z+w) and ATM(m) for τ=1(a), τ=2.1217(b), τ=2.5(c).
    Figure 5.  (Color online) The roots of characteristic equation (3.5) at E=(X,Y,Z,W,M) for τ=1(a), τ=2.1217(b), τ=2.5(c). (λ) and (λ) are real and imaginary parts of the roots. Green, blue and red dots represent the roots with negative, zero and positive real part, respectively.
    Figure 6.  (Color online) The potential landscapes of the concentrations of active p53(x) and total Mdm2 (y+z+w) at τ=1(a), τ=2.1217(b), τ=2.5(c).

    Next, Figures 4 and 5 show time series of the concentrations of active p53(x), total Mdm2(y+z+w), ATM(m) and the eigenvalues of Eq (3.5) for three typical time delays τ=1<τ0, τ=2.1217=τ0 and τ=2.5>τ0 to further verify the stability of system (2.1). As shown in Figure 4, system (2.1) converges to the stable equilibrium E at τ=1 (Figure 4(a)) and shows damped oscillation at τ=τ0 (Figure 4(b)), then is in a continuous oscillating state at τ=2.5 (Figure 4(c)). Accordingly, all roots of the characteristic equation (3.5) have negative real part at τ=1 (Figure 5(a)), and a pair of roots with zero real part appear at τ=2.1217 (Figure 5(b)), and some roots have positive real part at τ=2.5(Figure 5(c)).

    Furthermore, the global stability of p53 dynamics are explored through the potential landscapes of active p53(x) and total Mdm2(y+z+w) in Figure 6. The potential landscape U=ln(Pss) proposed by Wang et al. is related with the the steady state probability distribution Pss of the system (2.1) [29]. Pss can be obtained through simulating the corresponding stochastic differential equations of system (2.1) for a long time over many independent runs. The stochastic differential equations are obtained through adding Gaussian and white noise ζ(t) into right hand of each equation of system (2.1), where <ζ(t)ζ(t)>=2Dδ(tt), and <ζ(t)>=0, D is noise strength.As shown in the Figure 6(a), the potential landscape has a global minimum that corresponds to the global stable steady state. However, the potential landscapes in Figure 6(b) and 6(c) exhibit closed ring valleys which correspond to the stable limit cycle in system (2.1). The potential landscape at τ=2.1217 has wider attractive regions than the one at τ=2.5 since system (2.1) shows damped oscillation at τ=2.1217 and continuous oscillation at τ=2.5>τ0.

    Numerical simulations in this section are in agreement with the theoretical results in Section 3. In the following, we will further explore the effect of time delay τ and typical parameters on the oscillation dynamics of p53 from bifurcation perspective.

    To investigate how time delay τ affect p53 oscillation, we perform two-parameter bifurcation analyses with respect to time delay τ and several typical parameters, including the concentration of PDCD5(p), maximum production and degradation rates of p53 and Mdm2: vp53, dp53, vMdm2, dMdm2. Figures 711(a) show two-parameter bifurcation diagrams, where black solid lines hb represent Hopf bifurcation curves. For each two-parameter bifurcation diagram, several typical one-parameter bifurcation diagrams are given in Figures 711(b)(e), where black solid and dashed lines are stable and unstable steady states, respectively, and green solid dots are maxima and minima of stable limit cycles.

    Figure 7.  (Color online) (a) Two-parameter bifurcation diagram with respect to τ and the concentration of PDCD5(p). hb1 and hb2 represent Hopf bifurcation curves. Typical one-parameter bifurcation diagram of the concentration of active p53(x) with respect to τ for p=0.6(b), p=0.8(c), p=1.6(d), p=13(e). Black solid and dashed lines are stable and unstable equilibria, and green solid dots are the maxima and minima of the stable limit cycle. HB is Hopf bifurcation point.
    Figure 8.  (Color online) (a) Two-parameter bifurcation diagram with respect to τ and the maximum production rate of p53(vp53). hb represents Hopf bifurcation curve. Typical one-parameter bifurcation diagram of the concentration of active p53(x) with respect to τ for vp53=0.5(b), vp53=1(c), vp53=1.8(d). Black solid and dashed lines are stable and unstable equilibria, and green solid dots are the maxima and minima of the stable limit cycle. HB is Hopf bifurcation point.
    Figure 9.  (Color online)(a) Two-parameter bifurcation diagram with respect to τ and the maximum degradation rate of p53(dp53). hb represents Hopf bifurcation curve. Typical one-parameter bifurcation diagram of the concentration of active p53(x) with respect to τ for dp53=0.2(b), dp53=0.4(c), dp53=0.6(d). Black solid and dashed lines are stable and unstable equilibria, and green solid dots are the maxima and minima of the stable limit cycle. HB is Hopf bifurcation point.
    Figure 10.  (Color online) (a) Two-parameter bifurcation diagram with respect to τ and the maximum production rate of Mdm2(vMdm2). hb represents Hopf bifurcation curve. Typical one-parameter bifurcation diagram of the concentration of active p53(x) with respect to τ for vMdm2=0.1(b), vMdm2=0.4(c), vMdm2=0.75(d). Black solid and dashed lines are stable and unstable equilibria, and green solid dots are the maxima and minima of the stable limit cycle. HB is Hopf bifurcation point.
    Figure 11.  (Color online)(a) Two-parameter bifurcation diagram with respect to τ and the maximum degradation rate of Mdm2(dMdm2). hb represents Hopf bifurcation curve. Typical one-parameter bifurcation diagram of the concentration of active p53(x) with respect to τ for dMdm2=0.01(b), dMdm2=0.03(c), dMdm2=0.04(d). Black solid and dashed lines are stable and unstable equilibria, and green solid dots are the maxima and minima of the stable limit cycle. HB is Hopf bifurcation point.

    Figure 7(a) shows two-parameter bifurcation diagram with time delay τ and the concentration of PDCD5(p). Hopf bifurcation curves hb1 and hb2 on the figure divide the parameter region into three parts. p53 reaches a lower stable steady state for parameters on the left of the curve hb1, where p is less than 0.710 regardless of the value of τ. Then p53 oscillation appears for parameters between these two curves hb1 and hb2, where p53 always oscillates for any τ when 0.710<p<0.974 while p53 can oscillate when τ increases to certain value for 0.974<p<11.9. Also the value of τ on Hopf bifurcation curve is more larger for larger p. However, p53 reaches a higher stable steady state for any τ when p>11.9. For intuitiveness, one-parameter bifurcation diagrams of p53 concentration with respect to τ for four typical p are given in Figure 7(b)(e).

    Figures 810(a) show similar two-parameter bifurcation diagrams with respect to τ and vp53, dp53, vMdm2, respectively, where the Hopf bifurcation curves hb divides the parameter plane into two parts. p53 exhibits oscillation inside the curve hb and reaches a stable steady state outside the curve hb. As shown in Figures 810(a), time delay can induce p53 oscillation for moderate value of the rate constants while it has no effect on p53 dynamics for smaller and larger value of these parameters. Also, the value of time delay on Hopf bifurcation curve increases with the increase of vp53 and vMdm2 while the value of time delay decreases with the increase of dp53. Furthermore, from one-parameter bifurcation diagrams in Figures 810(b)(d), p53 reaches a lower stable steady state for smaller vp53 and vMdm2 and a higher stable steady state for larger vp53 and vMdm2, while the case is opposite for dp53.

    Besides, two-parameter bifurcation diagram with respect to τ and dMdm2 is shown in Figure 11(a), where p53 exhibits oscillation for any τ when dMdm2 is less than 0.0146 and reaches a stable steady state for any τ when dMdm2 is larger than 0.0355 while p53 changes from a stable steady state to oscillation with the increase of τ when dMdm2 varies between 0.0146 and 0.0355. These dynamics are shown on one-parameter bifurcation diagrams in Figure 11(b)(d).

    Therefore, bifurcation analyses further explore the effect of time delay τ on p53 oscillation.

    The oscillation dynamics of p53 plays a key role in deciding cell fate after DNA damage. The time delay in transcriptional and translational processes is an important factor to induce oscillation. In this study, we explore the effect of time delay of Mdm2 gene express in p53 gene regulatory network regulated by PDCD5 on p53 oscillation through stability theory and bifurcation analyses. Firstly, we give theorems that provide the conditions on the appearance of p53 oscillation for without and with time delays through stability analysis theory. Then, these theorems are verified through numerical simulations, including time series of p53 concentrations, one-parameter bifurcation diagram of p53 concentration versus time delay, the roots of the characteristic equations, and the potential landscapes of p53 and total Mdm2 concentrations. Furthermore, the effect of time delay and several typical parameters p, vp53, dp53, vMdm2 and dMdm2 in system (2.1) on p53 oscillation are explored through two-parameter bifurcation diagrams, which give boundary curves of p53 oscillation. Our results show that time delay can induce p53 oscillation for moderate value of most parameters while it has no effect on p53 dynamics for smaller and larger value of these parameters. Taken together, analyzing the effect of time delay on p53 oscillation will help us understand the mechanism of p53 oscillation.

    In this study, we explore the effect of time delay of Mdm2 gene express in p53 gene regulatory network regulated by PDCD5 on p53 oscillation. Our results have demonstrated that suitable time delay can induce p53 oscillation for moderate value of most parameters. However, the effect of multiple time delays in p53 gene regulatory network on p53 oscillation should be further explored. Besides, noise is common in gene regulatory work, it is worthwhile to explore the combined effect of noise and time delay on p53 dynamics. Also, it is meaningful to investigate the dynamics of the other gene regulatory networks or neural networks with time delay and noise for understanding their biological mechanism.

    This work is supported by the National Natural Science Foundation of China (Nos. 12062017 and 11702149), Natural Science Foundation of Inner Mongolia Autonomous Region of China (Grant 2021ZD01) and Collaborative Innovation Center for Grassland Ecological Security (Jointly Supported by the Ministry of Education of China and Inner Mongolia Autonomous Region). The authors acknowledge the reviewers for their valuable reviews and kind suggestions.

    The authors declare there is no conflicts of interest.



    [1] D. R. Jutagir, B. B. Blomberg, C. S. Carver, et al., Social well-being is associated with less pro-inflammatory and pro-metastatic leukocyte gene expression in women after surgery for breast cancer, Breast Cancer Res. Treat., 165 (2017), 169–180.
    [2] S. Katkuri and M. Gorantla, Awareness about breast cancer among women aged 15 years and above in urban slums: a cross sectional study, Int. J. Community Med. Public Health, 5 (2018), 929–932.
    [3] A. Pawlik, M. Slomi´ nska-Wojewódzka and A. Herman-Antosiewicz, Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants, Eur. J. Nutr., 55 (2016), 1165–1180.
    [4] D. L. Holliday and V. Speirs, Choosing the right cell line for breast cancer research, Breast Cancer Res., 13 (2011), 215–215.
    [5] R. L. Sutherland, R. E. Hall and I. W. Taylor, Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells, Cancer Res., 43 (1983), 3998–4006.
    [6] B. S. Katzenellenbogen, K. L. Kendra, M. J. Norman, et al., Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens, Cancer Res., 47(1987), 4355–4360.
    [7] A. Maton, Human biology and health, 1st edition, Prentice Hall, New Jersey, 1997.
    [8] L. V. Rao, B. A. Ekberg, D. Connor, et al., Evaluation of a new point of care automated complete blood count (CBC) analyzer in various clinical settings, Clin. Chim. Acta., 389 (2008), 120–125.
    [9] S. Bernard, E. Abdelsamad, P. Johnson, et al., Pediatric leukemia: diagnosis to treatment a review, J. Cancer Clin. Trials, 2(2017), 131.
    [10] A. Shankar, J. J. Wang, E. Rochtchina, et al., Association between circulating white blood cell count and cancer mortality: a population-based cohort study, Arch. Intern. Med., 166 (2006), 188–194.
    [11] K. Kim, J. Lee, N. J. Heo, et al., Differential white blood cell count and all-cause mortality in the Korean elderly, Exp. Gerontol., 48 (2013), 103–108.
    [12] C. Ruggiero, E. J. Metter, A. Cherubini, et al., White blood cell count and mortality in the Baltimore Longitudinal Study of Aging, J. Am. Coll. Cardiol., 49 (2007), 1841–1850.
    [13] D. S. Bell and J. H. O'Keefe, White cell count, mortality, and metabolic syndrome in the Baltimore longitudinal study of aging, J. Am. Coll. Cardiol., 50(2007), 1810.
    [14] G. D. Friedman and B. H. Fireman, The leukocyte count and cancer mortality, Am. J. Epidemiol., 133 (1991), 376–380.
    [15] M. H. Andersen, D. Schrama, P. thor Straten, et al., Cytotoxic T cells, J. Invest. Dermatol., 126 (2006), 32–41.
    [16] J. Folkman and R. Kalluri, Cancer without disease, Nature, 427 (2004), 787.
    [17] T. Fehm, V. Mueller, R. Marches, et al., Tumor cell dormancy: implications for the biology and treatment of breast cancer, Apmis, 116 (2008), 742–753.
    [18] N. Almog, Molecular mechanisms underlying tumor dormancy, Cancer Lett., 294 (2010), 139–146.
    [19] A. Friedman, Cancer as multifaceted disease, Math. Model. Nat. Pheno., 7(2012), 3–28.
    [20] R. Eftimie, J. L. Bramson and D. J. Earn, Interactions between the immune system and cancer: a brief review of non-spatial mathematical models, Bull. Math. Biol., 73 (2011), 2–32.
    [21] S. Banerjee and R. R. Sarkar, Delay-induced model for tumor–immune interaction and control of malignant tumor growth, Biosystems, 91 (2008), 268–288.
    [22] H. Moore and N. K. Li, A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction, J. Theor. Biol., 227 (2004), 513–523.
    [23] L. Anderson, S. Jang and J. Yu, Qualitative behavior of systems of tumor-CD4+-cytokine interactions with treatments, Math. Method. Appl. Sci., 38 (2015), 4330–4344.
    [24] A. d'Onofrio, Metamodeling tumor–immune system interaction, tumor evasion and immunotherapy, Math. Comput. Model., 47 (2008), 614–637.
    [25] A. Khar, Mechanisms involved in natural killer cell mediated target cell death leading to spontaneous tumour regression, J. Biosci., 22 (1997), 23–31.
    [26] T. Boon and P. van der Bruggen, Human tumor antigens recognized by T lymphocytes, J. Exp. Med., 183 (1996), 725–729.
    [27] D. Kirschner and J. C. Panetta, Modeling immunotherapy of the tumor–immune interaction, J. Math. Biol., 37 (1998), 235–252.
    [28] L. G. de Pillis, W. Gu and A. E. Radunskaya, Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations, J. Theor. Biol., 238 (2006), 841–862.
    [29] H. P. de Vladar and J. A. González, Dynamic response of cancer under the influence of immunological activity and therapy, J. Theor. Biol., 227 (2004), 335–348.
    [30] U. Fory´ s, J. Waniewski and P. Zhivkov, Anti-tumor immunity and tumor anti-immunity in a mathematical model of tumor immunotherapy, J. Biol. Syst., 14 (2006), 13–30.
    [31] R. W. De Boer, J. M. Karemaker and J. Strackee, Relationships between short-term blood-pressure fluctuations and heart-rate variability in resting subjects I: a spectral analysis approach, Med. Biol. Eng. Comput., 23 (1985), 352–358.
    [32] A. Cappuccio, M. Elishmereni and Z. Agur, Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model, Cancer Res., 66 (2006), 7293–7300.
    [33] N. Kronik, Y. Kogan, V. Vainstein, et al., Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics, Cancer Immunol. Immunother., 57 (2008), 425–439.
    [34] A. M. Jarrett, J. M. Bloom, W. Godfrey, et al., Mathematical modelling of trastuzumab-induced immune response in an in vivo murine model of HER2+ breast cancer, Math. Med. Biol., (2018), dqy014.
    [35] K. Annan, M. Nagel and H. A. Brock, A mathematical model of breast cancer and mediated immune system interactions, J. Math. Syst. Sci., 2(2012), 430–446.
    [36] R. Roe-Dale, D. Isaacson and M. Kupferschmid, A mathematical model of breast cancer treatment with CMF and doxorubicin, Bull. Math. Biol., 73 (2011), 585–608.
    [37] B. Ribba, N. H. Holford, P. Magni, et al., A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis, CPT Pharmacometrics Syst. Pharmacol., 3(2014), 1–10.
    [38] R. Bhat and C. Watzl, Serial killing of tumor cells by human natural killer cells–enhancement by therapeutic antibodies, PloS One, 2 (2007), e326.
    [39] T. Sutlu and E. Alici, Natural killer cell-based immunotherapy in cancer: current insights and future prospects, J. Intern. Med., 266 (2009), 154–181.
    [40] T. R. Stravitz, T. Lisman, V. A. Luketic, et al., Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography, J. Hepatol., 56 (2012), 129–136.
    [41] Y. Zhang, D. L. Wallace, C. M. De Lara, et al., In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection, Immunotherapy, 121(2007), 258–265.
    [42] P. Wilding, L. J. Kricka, J. Cheng, et al., Integrated cell isolation and polymerase chain reaction analysis using silicon microfilter chambers, Anal. Biochem., 257(1998), 95–100.
    [43] V. Pascal, N. Schleinitz, C. Brunet, et al., Comparative analysis of NK cell subset distribution in normal and lymphoproliferative disease of granular lymphocyte conditions, Eur. J. Immunol., 34(2004), 2930–2940.
    [44] L. de Pillis, T. Caldwell, E. Sarapata, et al., Mathematical modeling of the regulatory T cell effects on renal cell carcinoma treatment, Discrete Continuous Dyn. Syst. Ser. B, 18(2013), 915–943.
    [45] T. D. To, A. T. T. Truong, A. T. Nguyen, et al., Filtration of circulating tumour cells MCF-7 in whole blood using non-modified and modified silicon nitride microsieves, Int. J. Nanotechnol., 15(2018), 39–52.
    [46] C. Chen, Y. Chen, D. Yao, et al., Centrifugalfilter device for detection of rare cells with immuno-binding, IEEE T. Nanobiosci., 14(2015), 864–869.
    [47] P. Dua, V. Dua and E. N. Pistikopoulos, Optimal delivery of chemotherapeutic agents in cancer, Comput. Chem. Eng., 32(2008), 99–107.
    [48] A. G. López, J. M. Seoane and M. A. Sanjuán, A validated mathematical model of tumor growth including tumor–host interaction, cell-mediated immune response and chemotherap, Bull. Math. Biol., 76(2014), 2884–2906.
    [49] K. Liao, X. Bai and A. Friedman, The role of CD200–CD200R in tumor immune evasion, J. Theor. Biol., 328(2013), 65–76.
    [50] M. C. Martins, A. M. A. Rocha, M. F. P. Costa, et al., Comparing immune-tumor growth models with drug therapy using optimal control, AIP Conf. Proc., 1738(2016), 300005.
    [51] M. Fernandez, M. Zhou and L. Soto-Ortiz, A computational assessment of the robustness of cancer treatments with respect to immune response strength, tumor size and resistance, Int. J. Tumor Ther., 7(2018), 1–26.
    [52] D. F. Tough and J. Sprent, Life span of naive and memory T cells, Stem Cells, 13(1995), 242–249.
    [53] C. M. Rollings, L. V. Sinclair, H. J. M. Brady, et al., Interleukin-2 shapes the cytotoxic T cell proteome and immune environment–sensing programs, Sci. Signal., 11(2018), eaap8112.
    [54] E. M. Janssen, E. E. Lemmens, T. Wolfe, et al., CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes, Nature, 421(2003), 852.
    [55] I. Gruber, N. Landenberger, A. Staebler, et al., Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer, Anticancer Res., 33(2013), 2233–2238.
    [56] D. Homann, L. Teyton and M. B. Oldstone, Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory, Nat. Med., 7(2001), 913–919.
    [57] R. J. De Boer, D. Homann and A. S. Perelson, Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection, J. Immunol., 171(2003), 3928–3935.
    [58] G. T. Skalski and J. F. Gilliam, Functional responses with predator interference: viable alternatives to the Holling type II model, Ecology, 82(2001), 3083–3092.
    [59] H. Nawata, M. T. Chong, D. Bronzert, et al., Estradiol-independent growth of a subline of MCF-7 human breast cancer cells in culture, J. Biol. Chem., 256(1981), 6895–6902.
    [60] R. Clarke, N. Brünner, B. S. Katzenellenbogen, et al., Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo, Proc. Natl. Acad. Sci. USA, 86(1989), 3649–3653.
    [61] N. T. Telang, G. Li, M. Katdare, et al., The nutritional herb Epimedium grandiflorum inhibits the growth in a model for the Luminal A molecular subtype of breast cancer, Oncol. Lett., 13 (2017), 2477–2482.
    [62] T. A. Caragine, M. Imai, A. B. Frey, et al., Expression of rat complement control protein Crry on tumor cells inhibits rat natural killer cell–mediated cytotoxicity, Blood, 100 (2002), 3304–3310.
    [63] M. R. Müller, F. Grünebach, A. Nencioni, et al., Transfection of dendritic cells with RNA induces CD4-and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes, J. Immunol., 170 (2003), 5892–5896.
    [64] J. Chen, E. Hui, T. Ip, et al., Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (mcf-7) in nude mice, Clin. Cancer Res., 10(2004), 7703–7711.
    [65] P. V. Sivakumar, R. Garcia, K. S. Waggie, et al., Comparison of vascular leak syndrome in mice treated with IL21 or IL2, Comparative Med., 63 (2013), 13–21.
    [66] C.Wu, T.Motosha, H.A.Abdel-Rahman, etal., Freeandprotein-boundplasmaestradiol-17during the menstrual cycle, J. Clin. Endocrinol. Metab., 43(1976), 436–445.
    [67] E. Nikolopoulou, L. R. Johnson, D. Harris, et al., Tumour-immune dynamics with an immune checkpoint inhibitor, Lett. Biomath., 5(2018), S137–S159.
    [68] P. Vacca, E. Munari, N. Tumino, et al., Human natural killer cells and other innate lymphoid cells in cancer: friends or foes? Immunol. Lett., 201(2018), 14–19.
    [69] A. Cerwenka, J. Kopitz, P. Schirmacher, et al., HMGB1: the metabolic weapon in the arsenal of NK cells, Mol. Cell. Oncol., 3(2016), e1175538.
    [70] I. J. Fidler, Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125i-5-iodo-2'-deoxyuridine, J. Natl. Cancer Inst., 4(1970), 773–782.
    [71] G. G. Page and S. Ben-Eliyahu, A role for NK cells in greater susceptibility of young rats to metastatic formation, Dev. Comp. Immunol., 23(1999), 87–96.
    [72] O. E. Franco, A. K. Shaw, D. W. Strand, et al., Cancer associated fibroblasts in cancer pathogenesis, Semin. Cell Dev. Bio., 21(2010), 33–39.
    [73] G. P. Dunn, A. T. Bruce, H. Ikeda, et al., Cancer immunoediting: from immunosurveillance to tumor escape, Nat. Immunol., 3(2002), 991.
    [74] D. Mittal, M. M. Gubin, R. D. Schreiber, et al., New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape, Curr. Opin. Immunol., 27(2014), 16–25.
    [75] J. Nowak, P. Juszczynski and K. Warzocha, The role of major histocompatibility complex polymorphisms in the incidence and outcome of non-Hodgkin lymphoma, Curr. Immunol. Rev., 5(2009), 300–310.
    [76] J. G. B. Alvarez, M. González-Cao, N. Karachaliou, et al., Advances in immunotherapy for treatment of lung cancer, Cancer Biol. Med., 12(2015), 209–222.
    [77] M. E. Dudley and S. A. Rosenberg, Adoptive-cell-transfer therapy for the treatment of patients with cancer, Nat. Rev. Cancer, 3(2003), 666–675.
    [78] M. Su, C. Huang and A. Dai, Immune checkpoint inhibitors: therapeutic tools for breast cancer, Asian Pac. J. Cancer Prev., 17 (2016), 905–910.
    [79] M. Ebbo, L. Gérard, S. Carpentier, et al., Low circulating natural killer cell counts are associated with severe disease in patients with common variable immunodeficiency, EBioMedicine., 6(2016), 222–230.
    [80] S. H. Jee, J. Y. Park, H. Kim, et al., White blood cell count and risk for all-cause, cardiovascular, and cancer mortality in a cohort of Koreans, Am. J. Epidemiol., 162 (2005), 1062–1069.
    [81] W. B. Kannel, K. Anderson and T. W. Wilson, White blood cell count and cardiovascular disease: insights from the Framingham Study, Jama, 267 (1992), 1253–1256.
    [82] K. L. Margolis, J. E. Manson, P. Greenland, et al., Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study, Arch. Intern. Med., 165(2005), 500–508.
    [83] B. K. Duffy, H. S. Gurm, V. Rajagopal, et al., Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention, Am. J. Cardiol., 97 (2006), 993–996.
    [84] B. D. Horne, J. L. Anderson, J. M. John, et al., Which white blood cell subtypes predict increased cardiovascular risk? J. Am. Coll. Cardiol., 45(2005), 1638–1643.
    [85] R. N. O. Cobucci, H. Saconato, P. H. Lima, et al., Comparative incidence of cancer in HIV-AIDS patients and transplant recipients, Cancer Epidemiol., 36(2012), e69–e73.
    [86] C. Bodelon, M. M. Madeleine, L. F. Voigt, et al., Is the incidence of invasive vulvar cancer increasing in the United States? Cancer Causes Control, 20(2009), 1779–1782.
    [87] M. R. Shurin, Cancer as an immune-mediated disease, Immunotargets Ther., 1 (2012), 1–6.
    [88] J. S. Lawrence, Leukopenia: its mechanism and therapy, J. Chronic. Dis., 6(1957), 351–364.
    [89] P. Venigalla, B. Motwani, A. Nallari, et al., A patient on hydroxyurea for sickle cell disease who developed an opportunistic infection, Blood, 100(2002), 363–364.
    [90] M. Iwamuro, S. Tanaka, A. Bessho, et al., Two cases of primary small cell carcinoma of the stomach, Acta. Med. Okayama, 63(2009), 293–298.
    [91] A. O. O. Chan, I. O. L. Ng, C. M. Lam, et al., Cholestatic jaundice caused by sequential carbimazole and propylthiouracil treatment for thyrotoxicosis, Hong Kong Med. J., 9(2003), 377–380.
    [92] J. H. Goodchild and M. Glick, A different approach to medical risk assessment, Endod. Topics, 4(2003), 1–8.
    [93] S. E. Hankinson, Endogenous hormones and risk of breast cancer in postmenopausal women, Breast Dis., 24(2006), 3–15.
    [94] R. Kaaks, S. Rinaldi, T. J. Key, et al., Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition, Endocr. Relat. Cancer, 12(2005), 1071–1082.
    [95] S. A. Missmer, A. H. Eliassen, R. L. Barbieri, et al., Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women, J. Natl. Cancer Inst., 96(2004), 1856–1865.
    [96] A. A. Arslan, R. E. Shore, Y. Afanasyeva, et al., Circulating estrogen metabolites and risk for breast cancer in premenopausal women, Cancer Epidemiol. Biomarkers Prev., 18(2009), 2273–2279.
    [97] S. B. Brown and S. E. Hankinson, Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers, Steroids, 99(2015), 8–10.
    [98] L. C. Houghton, D. Ganmaa, P. S. Rosenberg, et al., Associations of breast cancer risk factors with premenopausal sex hormones in women with very low breast cancer risk, Int. J. Environ. Res. Public Health, 13(2016), 1066.
    [99] R. Kaaks, K. Tikk, D. Sookthai, et al., Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status-results from the EPIC cohortk, Int. J. cancer, 134(2014), 1947–1957.
    [100] A. Diefenbach, E. R. Jensen, A. M. Jamieson, et al., Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity, Nature, 413(2001), 165.
    [101] A. Iannello and D. H. Raulet, Cold Spring Harbor symposia on quantitative biology, 1st edition, Cold Spring Harbor Laboratory Press, New York, 2013.
    [102] M. B. Pampena and E. M. Levy, Natural killer cells as helper cells in dendritic cell cancer vaccines, Front. Immunol., 6 (2015), 1–8.
    [103] E. Vivier, S. Ugolini, D. Blaise, et al., Targeting natural killer cells and natural killer T cells in cancer, Nat. Rev. Immunol., 12(2012), 239–252.
    [104] G. Liu, X. Fan, Y. Cai, et al., Efficacy of dendritic cell-based immunotherapy produced from cord blood in vitro and in a humanized NSG mouse cancer model, Immunotherapy, 11(2019), 599–616.
    [105] M. Schnekenburger, M. Dicato and M. F. Diederich, Anticancer potential of naturally occurring immunoepigenetic modulators: A promising avenue? Cancer, 125(2019), 1612–1628.
    [106] X. Feng, L. Lu, K. Wang, et al., Low expression of CD80 predicts for poor prognosis in patients with gastric adenocarcinoma, Future Oncol., 15 (2019), 473–483.
    [107] X. Lai and A. Friedman, Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: a mathematical model, PloS One, 12 (2017), e0178479.
  • Reader Comments
  • © 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(9730) PDF downloads(1580) Cited by(25)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog